← Eichor
Condition: Cytomegalovirus Prophylaxis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cytomegalovirus Prophylaxis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patien
Phase 3 · 29 location(s) · Children's Oncology Group · NCT05711667The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Ce
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT06639854Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
Phase 4 · 12 location(s) · WeiShi · NCT07569653Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Rec
Phase N/A · 1 location(s) · University of Miami · NCT06494033Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Cent
NA · 1 location(s) · National Taiwan University Hospital · NCT07294547Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogenei
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06812598Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis
Phase 4 · 1 location(s) · First Affiliated Hospital Xi'an Jiaotong University · NCT07266467Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Phase 4 · 1 location(s) · Tufts Medical Center · NCT05626530Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Phase 2 · 1 location(s) · University of Pennsylvania · NCT06066957Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Phase 3 · 1 location(s) · University of Wisconsin, Madison · NCT06407232A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Phase 1 · 18 location(s) · Merck Sharp & Dohme LLC · NCT07199465CMV Immunity Monitoring in Lung Transplant Recipients
Phase 2 · 1 location(s) · NYU Langone Health · NCT05708755Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
Phase 3 · 5 location(s) · University of California, San Francisco · NCT06798909Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Phase 2 · 1 location(s) · Instituto de Investigación Marqués de Valdecilla · NCT04056533Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H
Phase N/A · 1 location(s) · Antonello Di Paolo, M.D., Ph.D. · NCT07013370Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
Phase 2 · 3 location(s) · Tata Memorial Centre · NCT07709013Breakthrough CMV Lung Transplant -Multicentre
Phase N/A · 1 location(s) · University of Alberta · NCT04439916Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Phase 4 · 2 location(s) · Camille N. Kotton, MD · NCT06958796Evaluation of CMV/EBV-CMI in Haploid HSCT
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06554197Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
Phase 2 · 1 location(s) · University Medical Centre Ljubljana · NCT05432778Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06575374
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.